Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC)
Affiliation
Department of Gynecology and Gynecological Oncology, Agaplesion Markus Hospital, Frankfurt am Main, GermanyIssue Date
2019
Metadata
Show full item recordAbstract
Brain metastases are common events in the natural course of many advanced solid cancers like breast, lung and renal cancer or melanoma with a cumulative risk of 10-30% in adults [1-3]. Non-small cell lung cancer (NSCLC) is associated with an increased risk for the development of brain metastases and the prognosis until recently has been poor except for some patients' subgroups and depending on the disease-specific GPA prognostic factors [4]. For patients receiving only best supportive care, average survival is about 3 months and it is assumed that through additional whole brain radiotherapy average survival may be improved up to 6-9 months in selected patients [5]. In recent years, complex treatment strategies for different solid tumors have been developed and this has impacted on the general management of brain metastases. Most of the studies on brain metastases have included different histological subtypes and therefore have made tumor- specific recommendations difficult. In this review, we discuss the current evidence on management of brain metastases and incorporate specific recent data on oncogenic-driven NSCLC in order to suggest recommendations on the optimal management of brain metastases in this subgroup of NSCLC where formal level I evidence is lacking.Citation
Andratschke N, Kraft J, Nieder C, Tay R, Califano R, Soffietti R, et al. Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer. 2019;129:63-71.Journal
Lung CancerDOI
10.1016/j.lungcan.2018.12.009PubMed ID
30797493Additional Links
https://dx.doi.org/10.1016/j.lungcan.2018.12.009Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2018.12.009
Scopus Count
Collections
Related articles
- Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.
- Authors: Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ
- Issue date: 2017 Jan
- The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care.
- Authors: Cerone MA, Mills TC, Sharpe R, McBride D, MacDonald M, MacMahon S, Mugalaasi H, Rehal P, Rettino A, Roberts H, Ross M, White DE, Peden J, Rawlinson J, Ho SN, Hollingsworth S, Popat S, Middleton G, Johnson P, Swanton C, SMP2 consortium
- Issue date: 2023 Jan
- Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters.
- Authors: Wang Y, Geller AE, Yan J
- Issue date: 2023 May 8
- Management of brain metastases in non-small cell lung cancer without actionable driver mutations-the need to dive deeper in the right 'pool'.
- Authors: Jablonska PA, Das A
- Issue date: 2023 Oct 31